Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion
mBio · 08.05.2024 · 15 (5)
DOI: 10.1128/mbio.00751-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 08.05.2024. Verfasst von Pei Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, Immune Evasion, COVID-19. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
The rapid evolution of SARS-CoV-2 variants presents a constant challenge to the global vaccination effort. In this study, we conducted a comprehensive investigation into two newly emerged variants, BA.2.87.1 and JN.1, focusing on their neutralization resistance, infectivity, antigenicity, cell-cell fusion, and spike processing. Neutralizing antibody (nAb) titers were assessed in diverse cohorts, including individuals who received a bivalent mRNA vaccine booster, patients infected during the BA.2.86/JN.1-wave, and hamsters vaccinated with XBB.1.5-monovalent vaccine. We found that BA.2.87.1 shows much less nAb escape from WT-BA.4/5 bivalent mRNA vaccination and JN.1-wave breakthrough infection sera compared to JN.1 and XBB.1.5. Interestingly, BA.2.87.1 is more resistant to neutralization by XBB.1.5-monovalent-vaccinated hamster sera than BA.2.86/JN.1 and XBB.1.5, but efficiently neutralized by a class III monoclonal antibody S309, which largely fails to neutralize BA.2.86/JN.1. Importantly, BA.2.87.1 exhibits higher levels of infectivity, cell-cell fusion activity, and furin cleavage efficiency than BA.2.86/JN.1. Antigenically, we found that BA.2.87.1 is closer to the ancestral BA.2 compared to other recently emerged Omicron subvariants including BA.2.86/JN.1 and XBB.1.5. Altogether, these results highlight immune escape properties as well as biology of new variants and underscore the importance of continuous surveillance and informed decision-making in the development of effective vaccines. IMPORTANCE This study investigates the recently emerged SARS-CoV-2 variants, BA.2.87.1 and JN.1, in comparison to earlier variants and the parental D614G. Varied infectivity and cell-cell fusion activity among these variants suggest potential disparities in their ability to infect target cells and possibly pathogenesis. BA.2.87.1 exhibits lower nAb escape from bivalent mRNA vaccinee and BA.2.86/JN.1-infected sera than JN.1 but is relatively resistance to XBB.1.5-vaccinated hamster sera, revealing distinct properties in immune reason and underscoring the significance of continuing surveillance of variants and reformulation of vaccines. Antigenic differences between BA.2.87.1 and other earlier variants yield critical information not only for antibody evasion but also for viral evolution. In conclusion, this study furnishes timely insights into the spike biology and immune escape of the emerging variants BA.2.87.1 and JN.1, thus guiding effective vaccine development and informing public health interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA.
- Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
- Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, Ohio, USA.
- Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, Ohio, USA.
- Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
ORCID-Profile: Linda J Saif, Jianrong Li, Shan-Lu Liu
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NCATS NIH HHS
- NICHD NIH HHS
- HHS | NIH | National Cancer Institute
- HHS | National Institutes of Health
- HHS | NIH | National Center for Advancing Translational Sciences
Zitieren
APA
Li, P., Liu, Y., Faraone, J. N., Hsu, C. C., Chamblee, M., Zheng, Y. M., Carlin, C., Bednash, J. S., Horowitz, J. C., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Jones, D., Li, J., Gumina, R. J., & Liu, S. L. (2024). Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. mBio, 15(5). https://doi.org/10.1128/mbio.00751-24
Vancouver
Li P, Liu Y, Faraone JN, Hsu CC, Chamblee M, Zheng YM, et al. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. mBio. 2024;15(5). doi:10.1128/mbio.00751-24
BibTeX
@article{Li2024,
author = {Li, Pei and Liu, Yajie and Faraone, Julia N and Hsu, Cheng Chih and Chamblee, Michelle and Zheng, Yi-Min and Carlin, Claire and Bednash, Joseph S and Horowitz, Jeffrey C and Mallampalli, Rama K and Saif, Linda J and Oltz, Eugene M and Jones, Daniel and Li, Jianrong and Gumina, Richard J and Liu, Shan-Lu},
title = {Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion},
journal = {mBio},
year = {2024},
volume = {15},
number = {5},
doi = {10.1128/mbio.00751-24}
}
EUVIMED